EUVIMEDEUVIMED entdecken
Crossref

Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice

Nicole Mastacouris, Rachel Tannenbaum, Andrew Strunk, Jonathan Koptyev, Pim Aarts, Raed Alhusayen, Falk G Bechara, Farida Benhadou, Vincenzo Bettoli, Alain Brassard, Debra Brown, Siew Eng Choon und 33 weitere

JAMA Dermatology · 2023

DOI: 10.1001/jamadermatol.2023.3282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Nicole Mastacouris und 44 weiteren Autor:innen. Beteiligte Einrichtung: Northwell Health, New Hyde Park, New York. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Although several clinician- and patient-reported outcome measures have been developed for trials in hidradenitis suppurativa (HS), there is currently no consensus on which measures are best suited for use in clinical practice. Identifying validated and feasible measures applicable to the practice setting has the potential to optimize treatment strategies and generate generalizable evidence that may inform treatment guidelines.

Objective

To establish consensus on a core set of clinician- and patient-reported outcome measures recommended for use in clinical practice and to establish the appropriate interval within which these measures should be applied. Evidence Review Clinician- and patient-reported HS measures and studies describing their psychometric properties were identified through literature reviews. Identified measures comprised an item reduction survey and subsequent electronic Delphi (e-Delphi) consensus rounds. In each consensus round, a summary of outcome measure components and scoring methods was provided to participants. Experts were provided with feasibility characteristics of clinician measures to aid selection. Consensus was achieved if at least 67% of respondents agreed with use of a measure in clinical practice.

Findings

Among HS experts, response rates for item reduction, e-Delphi round 1, and e-Delphi round 2 surveys were 76.4% (42 of 55), 90.5% (38 of 42), and 92.9% (39 of 42), respectively; among patient research partners (PRPs), response rates were 70.8% (17 of 24), 100% (17 of 17), and 82.4% (14 of 17), respectively. The majority of experts across rounds were practicing dermatologists with 18 to 19 years of clinical experience. In the final e-Delphi round, most PRPs were female (12 [85.7%] vs 2 males [11.8%]) and aged 30 to 49 years. In the final e-Delphi round, HS experts and PRPs agreed with the use of the HS Investigator Global Assessment (28 [71.8%]) and HS Quality of Life score (13 [92.9%]), respectively. The most expert-preferred assessment interval in which to apply these measures was 3 months (27 [69.2%]). Conclusions and Relevance An international group of HS experts and PRPs achieved consensus on a core set of HS measures suitable for use in clinical practice. Consistent use of these measures may lead to more accurate assessments of HS disease activity and life outcomes, facilitating shared treatment decision-making in the practice setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaFemaleHumansMaleConsensusDelphi TechniqueOutcome Assessment, Health CarePatient Reported Outcome MeasuresQuality of LifeAdultMiddle Aged

Autor:innen und Institutionen

  • Northwell Health, New Hyde Park, New York.
  • Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Sunnybrook Research Institute, Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.
  • Department of Dermatology, Venereology and Allergology, Ruhr-University, Bochum, Germany.
  • Department of Dermatology, Hôpital Universitaire de Bruxelles, CUB Hôpital Erasme, Université libre de Bruxelles, Brussels, Belgium.
  • Department of Medical Sciences, O.U. of Dermatology, Azienda Ospedaliera, University of Ferrara, Ferrara, Italy.

Zitieren

APA

Mastacouris, N., Tannenbaum, R., Strunk, A., Koptyev, J., Aarts, P., Alhusayen, R., Bechara, F. G., Benhadou, F., Bettoli, V., Brassard, A., Brown, D., Choon, S. E., Coutts, P., da Silva, D. L. F., Daveluy, S., Dellavalle, R. P., Del Marmol, V., Emtestam, L., Gebauer, K., …, & Garg, A. (2023). Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.3282

Vancouver

Mastacouris N, Tannenbaum R, Strunk A, Koptyev J, Aarts P, Alhusayen R, et al. Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2023.3282

BibTeX
@article{Mastacouris2023,
  author = {Mastacouris, Nicole and Tannenbaum, Rachel and Strunk, Andrew and Koptyev, Jonathan and Aarts, Pim and Alhusayen, Raed and Bechara, Falk G and Benhadou, Farida and Bettoli, Vincenzo and Brassard, Alain and Brown, Debra and Choon, Siew Eng and Coutts, Patricia and da Silva, Dimitri Luz Felipe and Daveluy, Steven and Dellavalle, Robert P and Del Marmol, Veronique and Emtestam, Lennart and Gebauer, Kurt and George, Ralph and Giamarellos-Bourboulis, Evangelos J and Goldfarb, Noah and Hamzavi, Iltefat and Hazen, Paul G and Horváth, Barbara and Hsiao, Jennifer and Ingram, John R and Jemec, Gregor B E and Kirby, Joslyn S and Lowes, Michelle A and Marzano, Angelo V and Matusiak, Lukasz and Naik, Haley B and Okun, Martin M and Oon, Hazel H and Orenstein, Lauren A V and Paek, So Yeon and Pascual, José C and Fernandez-Peñas, Pablo and Resnik, Barry I and Sayed, Christopher J and Thorlacius, Linnea and van der Zee, Hessel H and van Straalen, Kelsey R and Garg, Amit},
  title = {Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice},
  journal = {JAMA Dermatology},
  year = {2023},
  doi = {10.1001/jamadermatol.2023.3282}
}
Kostenlos starten →